Sotatercept  (Synonyms: ACE-011; MK-7962)

Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions^{[1][2][3][4][5]}.

Sotatercept (100 μg/mL) down-regulates the expression of VEGF, oncostatin-M (OSM), IL-6, BMP-2, MMP-1 and MMP13 secreted by SCs^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

77.63 kDa

1001080-50-7

Liquid

Colorless to light yellow

[Sotatercept]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [Homo sapiens ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized Activin A Protein, Human/Mouse/Rat (HEK293, HY-P70311) can bind Sotatercept. The EC₅₀ for this effect is 5.2 ng/mL.

• [1]. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215.  [Content Brief]

  [2]. Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12(5):586-97.  [Content Brief]

  [3]. Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23.  [Content Brief]

  [4]. Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013 Nov;53(11):1121-30.  [Content Brief]

  [5]. Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013 Feb;41(2):155-166.e17.  [Content Brief]